The Leukemia Lymphoma Society S Therapy Acceleration

The Leukemia Lymphoma Society S Therapy Acceleration Program vs Alan Kirshenbaum

The Leukemia Lymphoma Society S Therapy Acceleration Program is a venture capital based in New York, New York, United States. Alan Kirshenbaum is a private equity based in New York across 70 portfolio companies. Sector focus diverges: The Leukemia Lymphoma Society S Therapy Acceleration Program concentrates on generalist deals and Alan Kirshenbaum on Fintech, Proptech and SaaS.

• Investor type: The Leukemia Lymphoma Society S Therapy Acceleration Program — Venture Capital; Alan Kirshenbaum — Private Equity
• Headquarters: The Leukemia Lymphoma Society S Therapy Acceleration Program — New York, New York, United States; Alan Kirshenbaum — New York
• Portfolio companies: The Leukemia Lymphoma Society S Therapy Acceleration Program — not disclosed; Alan Kirshenbaum — 70
• Sectors: The Leukemia Lymphoma Society S Therapy Acceleration Program — not disclosed; Alan Kirshenbaum — Fintech, Proptech, SaaS

• The Leukemia & Lymphoma Society’s Therapy Acceleration Program — Venture Capital · New York, New York, United States · The Leukemia Lymphoma Society S Therapy Acceleration Program portfolio
• Alan Kirshenbaum — Private Equity · New York · 70 tracked deals · Alan Kirshenbaum portfolio

Similar investors

• Opto Custom GP 2023 LLC
• Thomas Teles
• Steven G. Glenn
• Edward Tsai
• Steven Leischner
• Thomas S. Giannetti
• Antler Special Opportunities GP I LLC
• Strategic Equity Capital NY LLC
• iCapital Strategies LLC
• Elodie Dupuy

Investors like The Leukemia Lymphoma Society S Therapy Acceleration Program · Investors like Alan Kirshenbaum · The Leukemia Lymphoma Society S Therapy Acceleration Program co-investors · Full investor directory